$REPL

2 theses

bullish 50%neutral 0%bearish 50%

Avg return (1y)

—

Win rate (1y)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Aug 24, 1:28 PM ET

$REPLSEC Form 4bearish

Patel Sushil · Chief Executive Officer at Replimune Group, Inc. · 70d agono track record yet

Sold 39,341 @ $12.97 avg · $510,253 · 2026-08-10

Form 4: Patel Sushil sold REPL

Patel Sushil (Chief Executive Officer at Replimune Group, Inc.) reported an open-market sale of 39,341 shares of REPL at an average $12.97, roughly $510,253, in a Form 4 filed 2026-08-12.

At post $15.24Now $14.92-2.1% since postedas of Aug 24, 1:28 PM ET

1d+0.1%

3d-1.8%

1w-2.8%

1m-15.2%

3m—

6m—

1y—

View filing on SEC.gov →

$REPLr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 111d ago20 prior · awaiting results

“long several of these”

5 of the 6 biotech names I posted 5 weeks ago hit their catalyst (and the 1 that hasn't)

FDA accepted RP1 BLA resubmission for advanced melanoma with AdCom expected late July and PDUFA Aug 2. Regulatory reversal narrative on strong data has driven stock roughly 2-3x higher from flag/lows.

Now $14.92as of Aug 24, 1:28 PM ET

original post →

End of results.